It's more important than ever before for your elected officials to hear from you - don't miss your chance to turn Capitol ...

Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...

Lupus affects women at disproportionately high rates— roughly 9 out of 10 patients are female —and research consistently ...

Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the ...

Lupus is often marked by flares, which is when symptoms are usually more obvious.

Higher levels of antimitochondrial antibodies in patients with systemic lupus erythematosus are tied to a higher risk for ...

Low proteinuria does not indicate better kidney outcomes or treatment response in patients with lupus nephritis; ...

Telitacicept, a dual inhibitor of the cytokines B-lymphocyte stimulator and a proliferation-inducing ligand, showed efficacy ...

Today, the Lupus Research Alliance, the world's largest private funder of lupus research, announced the formation of a new philanthropic venture fund Lupus Ventures. The Fund is dedicated to advancing ...

Johnson & Johnson (JNJ) shares are in focus after two pipeline updates: a Phase 2b win for nipocalimab in systemic lupus ...

We’re all mostly human. 8% of your genome comes from viruses. In A Nutshell Scientists captured the first detailed images of ...

— -- Selena Gomez is finally opening up about the real reason she took some time off in 2013: The pop star was busy with treatment for lupus. In a new interview with Billboard, the actress-singer ...